Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for HLA Desensitization Prior to Heart Transplant
NCT05300451Phase 2Enrolling by invitation
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Darzalex Faspro in Human Leukocyte Antigen Sensitization. Started Mar 2022; status: enrolling by invitation.
02
Drugs
Darzalex Faspro
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT05300451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300451.